Print Page     Close Window

Investor Overview

Jounce Therapeutics is dedicated to transforming the treatment of cancer.

Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.

Recent Press Releases

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine fo...
Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference...
Jounce Therapeutics to Present at Upcoming Investor Conferences in September...

View More Releases
NASDAQ GS JNCE (Common Stock)
$5.58 - 0.25 (4.29%)
Stock chart for: JNCE.O.  Currently trading at $5.58 with a 52 week high of $29.25 and a 52 week low of $5.51.
10/19/18 4:00 p.m. ET
Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.

Upcoming Events

There are currently no events scheduled.

View More Events